Cell therapy and other neuroregenerative strategies in Parkinson's disease (II);Terapia celular y otras estrategias neurorregenerativas en la enfermedad de Parkinson (II)

Revista de Neurologia

Volumn 41, Issue 11, 2005, Pages 684-693

  Mínguez Castellanos, Adolfo ^a   Escamilla Sevilla, F ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

Cell therapy; GDNF; Neuroregeneration; Neurorestoration; Neurotrophic factors; Parkinson's disease; Transplantation

Indexed keywords

CYCLOSPORIN A; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; PLACEBO; DOPAMINE; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT;

ADRENAL MEDULLA; ASTROCYTE; CAROTID BODY; CELL AGGREGATION; CELL IMMORTALIZATION; CELL THERAPY; CLINICAL TRIAL; DNA MODIFICATION; DOPAMINERGIC SYSTEM; ENCAPSULATION; FIBROBLAST; GENE THERAPY; GRAFT REJECTION; HUMAN; NERVE REGENERATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PIGMENT EPITHELIUM; REVIEW; STEM CELL; XENOTRANSPLANTATION; BIOLOGICAL THERAPY; BRAIN TRANSPLANTATION; CORPUS STRIATUM; METABOLISM; PATHOLOGY; PHYSIOLOGY;

BRAIN TISSUE TRANSPLANTATION; CORPUS STRIATUM; DOPAMINE; GENE THERAPY; HUMANS; NERVE GROWTH FACTORS; NERVE REGENERATION; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; TISSUE THERAPY;

EID: 33644842451     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4111.2005276     Document Type: Review

References (104)

1. Mínguez A, Escamilla F. Terapia celular y otras estrategias neurorregenerativas en la enfermedad de Parkinson (I). Rev Neurol 2005; 41: 604-14.
2. Freeman TB, Wojak J, Brandeis L, Michel J, Pearson J, Flamm E. Cross-species intracerebral grafting of embryonic swine dopaminergic neurons. Prog Brain 1988; 78: 473-7.
3. Isacson O, Deacon TW, Pakzaban P, Galpern WR, Dinsmore J, Burns LH. Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nat Med 1995; 11: 1189-94.
4. Galpern WR, Burns LH, Deacon TW, Dinsmore J, Isacson O. Xenotransplantation of porcine embryonic ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology. Exp Neurol 1996; 140: 1-13.
5. Schumacher JM, Ellias SA, Palmer EP, Kott HS, Dinsmore J, Dempsey PK, et al. Transplantation of embryonic porcine mesencephalic tissue in patients with Parkinson's disease. Neurology 2000: 54; 1042-9.
6. Deacon T, Schumacher J, Dinsmore J, Thomas C, Palmer P, Kott S, et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat Med 1997; 3: 350-3.
7. Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol 2003; 53 (Suppl 3): S87-99.
8. Subramanian T, Marchionini D, Potter EM, Cornfeldt ML. Striatal xenotransplantation of human retinal pigment epithelial cells atthached to microcarriers in hemiparkinsonian rats ameliorates behavioural deficits without provoking a host immune response. Cell Transplant 2002; 11: 207-14.
9. Watts RL, Raiser CD, Stover NP, Cornfeldt ML, Schweikert AW, Allen RC, et al. Stereotaxic intraestriatal implantation of human retinal pigment epithelial cells attached to gelatine microcarriers: a potential new cell therapy for Parkinson's disease. J Neural Transm Suppl 2003; 65: 215-27.
10. 2 in type I chemoreceptor cells. Science 1988; 241: 580-2.
11. 2+ entry and quantal dopamine secretion in carotid body glomus cells. Proc Natl Acad Sci USA 1994; 91: 10208-11.
12. Bing GY, Notter MF, Hansen JT, Gash DM. Comparison of adrenal medullary, carotid body and PC12 cell grafts in 6-OHDA lesioned rats. Brain Res Bull 1988; 20: 399-406.
13. Espejo E, Montoro RJ, Armengol JA, López-Barneo J. Cellular and functional recovery of parkinsonian rats after intrastriatal transplantation of carotid body cell aggregates. Neuron 1998; 20: 197-206.
14. Toledo-Aral JJ, Méndez-Ferrer S, Pardal R, López-Barneo J. Dopaminergic cells of the carotid body: physiological significance and possible therapeutic applications in Parkinson's disease. Brain Res Bull 2002; 57: 847-53.
15. Toledo-Aral JJ, Méndez-Ferrer S, Pardal R, Echevarría M, López-Barneo J. Throfic restoration of the nigrostriatal dopaminergic pathway in long-term carotid body grafted parkinsonian rats. J Neurosci 2003; 23: 141-8.
16. McGregor KH, Gil J, Lahiri S. A morphometric study of the carotid body in chronically hypoxic rats. J Appl Physiol 1984; 57: 1430-8.
17. Czyzyk-Krzeska MF, Bayliss DA, Lawson EE, Millhorn DE. Regulation of tyrosine hydroxylase gene expression in the rat carotid body by hypoxia. J Neurochem 1992; 58: 1538-56.
18. Nosrat CA, Tomac A, Lindqvist E, Lindskog S, Humpel C, Stromberg I, et al. Cellular expression of GDNF mRNA suggest multiple functions inside and outside the nervous system. Cell Tissue Res 1996; 286: 191-207.
19. Leitner ML, Wang LH, Osborne PA, Golden JP, Milbrandt J, Johnson EM Jr. Expression and function of GDNF family ligands and receptors in the carotid body. Exp Neurol 2005; 191 (Suppl 1): S68-79.
20. Villadiego J, Méndez-Ferrer S, Valdés-Sánchez T, Silos-Santiago I, Fariñas I, López-Barneo J, et al. Selective glial cell line-derived neurotrophic factor production in adult dopaminergic carotid body cells in situ and after intrastriatal transplantation. J Neurosci 2005 25: 4091-8.
21. Honda Y. Respiratory and circulatory activities in carotid body ressected humans. J Appl Physiol 1992; 73: 1-8.
22. Luquin MR, Montoro RJ, Guillen J, Saldise L, Insausti R, Del Río J, et al. Recovery of chronic parkinsonian monkeys by autotransplants of carotid body cell aggregates into putamen. Neuron 1999; 22: 743-50.
23. Hao G, Yao Y, Wang J, Zhang L, Viroonchatapan N, Wang ZZ. Intraestriatal grafting of glomus cells ameliorates behavioural defects of parkinsonian rats. Physiol Behav 2002; 77: 519-25.
24. Shukla S, Agrawal AK, Chaturvedi RK, Seth K, Srivastava N, Sinha C, et al. Co-transplantation of carotid body and ventral mesencephalic cells as an alternative approach towards functional restoration in 6-hydroxydopamine- lesioned rats: implications for Parkinson's disease. J Neurochem 2004; 91: 274-84.
25. Arjona V, Mínguez-Castellanos A, Montoro RJ, Ortega A, Escamilla F, Toledo-Aral JJ, et al. Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 2003; 53: 321-30.
26. Mínguez-Castellanos A. Trasplante de agregados celulares del cuerpo carotídeo en pacientes con enfermedad de Parkinson [tesis doctoral]. Granada: Universidad de Granada; 2005.
27. López-Lozano JJ, Mata M, Bravo G, Grupo de Trasplantes Neurales de la Clínica Puerta de Hierro. Trasplantes neurales en la enfermedad de Parkinson: experiencia de la Clínica Puerta de Hierro y estado actual. Neurología 2000; 15 (Supl 5): 62-79.
28. Nakai M, Itakura T, Kamei I, Nakai K, Naka Y, Imai H, et al. Autolo gous transplantation of the superior cervical ganglion into the brain of parkinsonian monkeys. J Neurosurg 1990; 72: 91-5.
29. Itakura T, Uematsu Y, Nakao N, Nakai E, Nakai K. Transplantation of autologous sympathetic ganglion into the brain with Parkinson's disease: long-term follow-up of 35 cases. Stereotact Funct Neurosurg 1997; 69: 112-5.
30. Hovarth M, Pasztor E, Palkovits M, Solyom A, Tarczy M, Lekka N, et al. Autotransplantation of superior cervical ganglion to the caudate nucleus in three patients with Parkinson's disease (preliminary report). Neuorosurg Rev 1990; 13: 119-22.
31. Nakao N, Kakishita K, Uematsu Y, Yoshimasu T, Bessho T, Nakai K, et al. Enhancement of the response to levodopa therapy after intrastriatal transplantation of autologous sympathetic neurons in patients with Parkinson disease. J Neurosurg 2001; 95: 275-84.
32. Nakao N, Shintani-Mizushima A, Kakishita K, Itakura T. The ability of grafted human sympathetic neurons to synthesize and store dopamine: a potential mechanism for the clinical effect of sympathetic neuron autografts in patients with Parkinson's disease. Exp Neurol 2004; 188: 65-73.
33. 1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ. J Neurosci 2001; 21: 9888-95.
34. Borlongan CV, Cameron DF, Saporta S, Sanberg PR. Intracerebral transplantation of testis-derived Sertoli cells promotes functional reocovery in female reats with 6-hidroxydopamine-induced hemiparkinsonism. Exp Neurol 1997; 148: 388-99.
35. Liu HW, Kuang YJ, Wu JC, Ma KH, Wang SD, Liu JC. Intrastriatal transplantation of Sertoli cells may improve amphetamine-induced rotation and tyrosine hydroxylase immunoreactivity of the striatum in hemiparkinsonian rats. Brain Res 1999; 838: 22-233.
36. Othberg AI, Willing AE, Cameron DF, Anton A, Saporta S, Freeman TB, et al. Trophic effect of porcine Sertoli cells on rat and human ventral mesencephalic cells and hNT neurons in vitro. Cell Transplant 1998; 7: 157-64.
37. Sanberg PR, Borlongan CV, Othberg AI, Saporta S, Freeman TB, Cameron DF. Testis-derived Sertoli cells have a trophic effect on dopamine neurons and alleviate hemiparkinsonism in rats. Nat Med 1997; 3: 1129-32.
38. Subramanian T, Emerich DF, Bakay RA, Hoffman JM, Goodman MM, Shoup TM, et al. Polymer-encapsulated PC-12 cells demonstrate highaffinity uptake of dopamine in vitro and 18F-dopa uptake and metabolism after intracerebral implantation in nonhuman primates. Cell Transplant 1997; 6: 469-77.
39. Date I, Shingo T, Yoshida H, Fujiwara K, Kobayashi K, Ohmoto T. Grafting of encapsulated dopamine-secreting cells in Parkinson's disease: long-term primate study. Cell Transplant 2000; 9: 705-9.
40. Yoshida H, Date I, Shingo T, Fujiwara K, Kobayashi K, Miyoshi Y, et al. Stereotactic transplantation of a dopamine-producing capsule into the striatum for treatment of Parkinson disease: a preclinical primate study. J Neurosurg 2003; 98: 874-81.
41. Bencsics C, Wachtel SR, Milstien S, Hatakeyama K, Becker JB, Kang UJ. Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts. J Neurosci 1996;16: 4449-56.
42. Leff SE, Rendahl KG, Spratt SK, Kang UJ, Mandel RJ. In vivo LDOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTPcyclohydrolase I with tyrosine hydroxylase. Exp Neurol 1998; 151: 249-64.
43. Chen S, Xianwen C, Dehua X, Zhenguo L, Lingfei X, Smith SW, et al. Behavioral correction of Parkinsonian rats following the transplantation of immortalized fibroblasts genetically modified with TH and GCH genes. Parkinsonism Relat Disord 2003; 9 (Suppl 2): S91-7.
44. Frim DM, Uhler TA, Galpern WR, Beal MF, Breakefield XO, Isacson O. Implanted fibroblasts genetically engineered to produce brainderived neurotrophic factor prevent MPTP toxicity to dopaminergic neurons in the rat. Proc Natl Acad Sci USA 1994; 91: 5104-8.
45. Levivier M, Przedborski S, Bencsics C, Kang UJ. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1995; 15: 7810-20.
46. Duan D, Yang H, Zhang J, Zhang J, Xu Q. Long-term restoration of nigrostriatal system function by implanting GDNF genetically modified fibroblasts in a rat model of Parkinson's disease. Exp Brain Res 2005; 161: 316-24.
47. Cortez N, Trejo F, Vergara P, Segovia J. Primary astrocytes retrovirally transduced with a tyrosine hydroxylase transgene driven by a glial-specific promoter elicit behavioral recovery in experimental parkinsonism. J Neurosci Res 2000; 59: 39-46.
48. Hida H, Hashimoto M, Fujimoto I, Nakajima K, Shimano Y, Nagatsu T, et al. Dopa-producing astrocytes generated by adenoviral transduction of human tyrosine hydroxylase gene: in vitro study and transplantation to hemiparkinsonian model rats. Neurosci Res 1999; 35: 101-12.
49. Park KW, Eglitis MA, Mouradian MM. Protection of nigral neurons by GDNF-engineered marrow cell transplantation. Neurosci Res 2001; 40: 315-23.
50. Hoshimaru M, Ray J, Sah DW, Gage FH. Differentiation of the immortalized adult neuronal progenitor cell line HC2S2 into neurons by regulatable suppression of the v-myc oncogene. Proc Natl Acad Sci USA 1996; 93: 1518-23.
51. Nakao N, Yokote H, Nakai K, Itakura T. Promotion of survival and regeneration of nigral dopamine neurons in a rat model of Parkinson's disease after implantation of embryonal carcinoma-derived neurons genetically engineered to produce glial cell line-derived neurotrophic factor. J Neurosurg 2000; 92: 659-70.
52. Yasuhara T, Shingo T, Muraoka K, Kobayashi K, Takeuchi A, Yano A, et al. Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J Neurosurg 2005; 102: 80-9.
53. Wagner J, Akerud P, Castro DS, Holm PC, Canals JM, Snyder EY, et al. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat Biotechnol 1999; 17: 653-9.
54. Akerud P, Canals JM, Snyder EY, Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci 2001; 21: 8108-18.
55. Deacon T, Dinsmore J, Costantini LC, Ratliff J, Isacson O. Blastuladerived stem cells can differentiate into dopaminergic and serotoninergic neurons after transplantation. Exp Neurol 1998; 149: 28-41.
56. Björklund LM, Sánchez-Pernaute R, Chung S, Andersson T, Chen IY, McNaught KSP, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002; 99: 2344-9.
57. Arenas E. Stem cells in the treatment of Parkinson's disease. Brain Res Bull 2002; 57: 795-808.
58. Kim JH, Auerbach JM, Rodríguez-Gómez JA, Velasco I, Gavin D, Lumelsky N, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002; 418: 50-6.
59. Kawasaki H, Suemori H, Mizuseki K, Watanabe K, Urano F, Ichinose H, et al. Generation of dopaminergic neurons and pigmented epithelia from primate ES cells by stromal cell-derived inducing activity. Proc Natl Acad Sci USA 2002; 99: 1580-5.
60. Takagi Y, Takahashi J, Saiki H, Morizane A, Hayashi T, Kishi Y, et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 2005; 115: 102-9.
61. Wakayama T, Tabar V, Rodríguez I, Perry AC, Studer L, Mombaerts P. Differentiation of embryonic stem cell lines generated from adult somatic cells by nuclear transfer. Science 2001; 292: 740-3.
62. Barberi T, Klivenyi P, Calingasan NY, Lee H, Kawamata H, Loonam K, et al. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol 2003; 21: 1200-7.
63. Studer L, Tabar V, McKay RDG. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci 1998; 1: 290-5.
64. Carvey PM, Ling ZD, Sortwell CE, Pitzer MR, McGuire SO, Storch A, et al. A clonal line of mesencephalic progenitor cells converted to dopamine neurons by hematopoietic cytokines: a source of cells for transplantation in Parkinson's disease. Exp Neurol 2001; 171: 98-108.
65. Storch A, Paul G, Csete M, Boehm BO, Carvey PM, Kupsh A, et al. Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp Neurol 2001; 170: 317-25.
66. Sánchez-Pernaute R, Studer L, Bankiewicz KS, Major EO, Mckay RDG. In vitro generation and transplantation of precursor-derived human dopamine neurons. J Neurosci Res 2001; 65: 284-8.
67. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-González XR, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002; 418: 41-9.
68. Walczak P, Chen N, Hudson JE, Willing AE, Garbuzova-Davis SN, Song S, et al. Do hematopoietic cells exposed to a neurogenic environment mimic properties of endogenous neural precursors? J Neurosci Res 2004; 76: 244-54.
69. Wagers AJ, Sherwood RI, Christensen JL, Weissman IL. Little evidence for developmental plasticity of adult hematopoietic stem cells. Science 2002; 297: 2256-9.
70. Li Y, Chen J, Wang L, Zhang L, Lu M, Chopp M. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett 2001; 316: 67-70.
71. Zigova T, Song S, Willing AE, Hudson JE, Newman MB, Saporta S, et al. Human umbilical cord blood cells express neural antigens after transplantation into the developing rat brain. Cell Transplant 2002; 11: 265-74.
72. Álvarez-Buylla A, García-Verdugo JM. Neurogenesis in adult subventricular zone. J Neurosci 2002; 22: 629-34.
73. Maslov AY, Barone TA, Plunkett RJ, Pruitt SC. Neural stem cell detection, characterization, and age-related changes in the subventricular zone of mice. J Neurosci 2004; 24: 1726-33.
74. Lie DC, Dziewczapolski G, Willhoite AR, Kaspar BK, Shults CW, Gage FH. The adult substantia nigra contains progenitor cells with neurogenic potential. J Neurosci 2002; 22: 6639-49.
75. Lim DA, Flames N, Collado L, Herrera DG. Investigating the use of primary adult subventricular zone neural precursor cells for neuronal replacement therapies. Brain Res Bull 2002; 57: 759-64.
76. Rakic P. Adult neurogenesis in mammals: an identity crisis. J Neurosci 2002; 22: 614-8.
77. Moris G, Vega JA. Factores neurotróficos: fundamentos para su aplicación clínica. Neurología 2003; 18: 18-28.
78. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993; 260: 1130-2.
79. Hoffer BJ, Hoffman A, Bowenkamp K, Huettl P, Hudson J, Martin D, et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994; 182: 107-11.
80. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995; 373: 335-9.
81. Winkler C, Sauer H, Lee CS, Bjorklund A. Short-term GDNF treatment provides long-term rescue of lesioned nigral dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1996; 16: 7206-15.
82. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996; 380: 252-5.
83. Chauhan NB, Siegel GJ, Lee JM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson's disease brain. J Chem Neuroanat 2001; 21: 277-88.
84. Grondin R, Zhang Z, Yi A, Cass WA, Maswood N, Andersen AH, et al. Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. Brain 2002; 125: 2191-201.
85. Brundin P. GDNF treatment in Parkinson's disease: time for controlled clinical trials? Brain 2002; 125: 2149-51.
86. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003; 60: 69-73.
87. Kordower JH, Palfi SP, Chen EY, Ma SY, Sendera T, Cochran EJ, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in Parkinson's disease. Ann Neurol 1999; 46: 419-24.
88. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003; 9: 589-95.
89. Jollivet C, Aubert-Pouessel A, Clavreul A, Venier-Julienne MC, Remy S, Montero-Menei CN, et al. Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. Biomaterials 2004; 25: 933-42.
90. García-Miniet R, Alberti-Amador E, Castellano-Ortega MR. Terapia génica en el tratamiento de la enfermedad de Parkinson. Rev Neurol 2003; 36: 1073-7.
91. During MJ, Naegele JR, O'Malley KL. Long-term behavioral recovery in parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994; 266: 1399-403.
92. Mandel RJ, Rendahl KG, Spratt SK, Snyder RO, Cohen LK, Leff SE. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 1998; 18: 4271-84.
93. Leone P, McPhee WJ, Janson CG, Davidson BL, Freese A, During MJ. Multi-site partitioned delivery of human tyrosine hydroxylase gene with phenotypic recovery in Parkinsonian rats. Neuroreport 2000; 11: 1145-51.
94. Shen Y, Muramatsu SI, Ikeguchi K, Fujimoto KI, Fan DS, Ogawa M, et al. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 2000; 11: 1509-19.
95. Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys: in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000; 164: 2-14.
96. Bilang-Bleuel A, Revah F, Colin P, Locquet I, Robert JJ, Mallet J, et al. Intrastriatal injection of an adenoviral vector expressing glial-cell- linederived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1997; 94: 8818-23.
97. Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000; 20: 4686-700.
98. Kordower JH, Emborg ME, Bloch J, Ma SY, Chu Y, Leventhal L, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290: 767-73.
99. Palfi S, Leventhal L, Chu Y, Ma SY, Emborg M, Bakay R, et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 2002; 22: 4942-54.
100. Mochizuki H, Mizuno Y. Gene therapy for Parkinson's disease. J Neural Transm Suppl 2003; 65: 205-13.
101. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002; 298: 425-9.
102. During MJ, Kaplitt MG, Stern MB, Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 2001; 12: 1589-91.
103. Schlachetzki F, Zhang Y, Boado RJ, Pardridge WM. Gene therapy of the brain: the trans-vascular approach. Neurology 2004; 62: 1275-81.
104. Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 2003; 14: 1-12.